Gradient Investments LLC Purchases 12,436 Shares of Sanofi $SNY

Gradient Investments LLC raised its position in Sanofi (NASDAQ:SNY) by 55.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 34,816 shares of the company’s stock after acquiring an additional 12,436 shares during the quarter. Gradient Investments LLC’s holdings in Sanofi were worth $1,687,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC lifted its stake in shares of Sanofi by 52.6% in the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after purchasing an additional 1,869 shares during the period. AQR Capital Management LLC grew its position in Sanofi by 107.2% during the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock valued at $1,693,000 after buying an additional 15,791 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Sanofi by 1.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock valued at $2,732,000 after buying an additional 752 shares during the period. Sivia Capital Partners LLC increased its holdings in Sanofi by 5.4% during the second quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock valued at $326,000 after buying an additional 347 shares during the last quarter. Finally, TD Waterhouse Canada Inc. raised its position in Sanofi by 12.8% in the second quarter. TD Waterhouse Canada Inc. now owns 3,232 shares of the company’s stock worth $159,000 after acquiring an additional 366 shares during the period. 14.03% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Performance

Shares of NASDAQ SNY opened at $44.77 on Tuesday. The stock has a market cap of $109.19 billion, a PE ratio of 12.44, a price-to-earnings-growth ratio of 1.15 and a beta of 0.45. Sanofi has a 1 year low of $43.32 and a 1 year high of $56.93. The firm has a fifty day moving average price of $46.40 and a 200-day moving average price of $48.02. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.73.

Analyst Ratings Changes

SNY has been the topic of several analyst reports. HSBC reiterated a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, March 19th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sanofi in a report on Friday, January 16th. TD Cowen restated a “hold” rating on shares of Sanofi in a research report on Tuesday, December 30th. Finally, Guggenheim downgraded Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $61.50.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.